MeSH Terms
Aged
Antineoplastic Agents/therapeutic use
CTLA-4 Antigen/antagonists & inhibitors
Graft Rejection/etiology
Graft Survival
Humans
Kidney Failure, Chronic/complications,surgery
Kidney Transplantation/adverse effects
Male
Melanoma/drug therapy,etiology,secondary
Postoperative Complications
Prognosis
Programmed Cell Death 1 Receptor/antagonists & inhibitors
Risk Factors
Skin Neoplasms/drug therapy,etiology,pathology
Transplant Recipients
Chemicals
Antineoplastic Agents
CTLA-4 Antigen
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Alhamad T
Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO. | Transplant Epidemiology Research Collaboration (TERC), Institute of Public Health, Washington University in St. Louis, St. Louis, MO.
Venkatachalam K
Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.
Linette G P
Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.
Brennan D C
Renal Division, Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO.